Core Insights - ADC Therapeutics is focused on expanding the use of its approved product ZYNLONTA in earlier lines of DLBCL and indolent lymphomas, with significant accomplishments expected in 2025 [2] - The company aims to derisk its portfolio of trials for ZYNLONTA and strengthen its capital position through restructuring and equity raises [2] - Key data disclosures for multiple studies are anticipated in 2025, with expected growth starting in 2027 and continuing into 2028 and beyond [3] Company Overview - ADC Therapeutics operates in the ADC (Antibody-Drug Conjugate) space and has an approved product, ZYNLONTA, which is a CD19 directed ADC using a PBD-based warhead [3] - The company is preparing for final data disclosures in 2025, which are crucial for derisking its clinical trials [3] - The anticipated approval and compendia inclusion for multiple new uses of ZYNLONTA are expected to drive growth from 2027 onwards [3]

Core Viewpoint - ADC Therapeutics SA is a global leader in antibody drug conjugates (ADCs) and will present at the J.P. Morgan Healthcare Conference on January 15, 2026 [1] Company Overview - ADC Therapeutics is focused on transforming treatment for patients through its portfolio, which includes ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC [3] - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey, emphasizing innovation in ADC development from clinical to manufacturing and commercialization [5] Product Development - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [4] - The company is also developing a next-generation PSMA-targeting ADC that utilizes a differentiated exatecan-based payload with a novel hydrophilic linker [4]

Core Insights - ADC Therapeutics (NYSE:ADCT) is highlighted as a promising investment opportunity, particularly in the context of its lymphoma treatment developments [1][2] - Recent positive interim Phase Ib data from the LOTIS-7 trial has led to reaffirmed buy ratings from analysts, with price targets set at $10.00 by Guggenheim and $5.00 by RBC Capital [1][2] Trial Results - The LOTIS-7 trial demonstrated an overall response rate of 89.8% and a complete response rate of 77.6% among 49 efficacy-evaluable patients, indicating strong efficacy for ZYNLONTA in treating relapsed or refractory diffuse large B-cell lymphoma [3] - The trial results support the potential of ZYNLONTA and glofitamab as leading bispecific antibody-based combinations for patients with 2L+ DLBCL [3] Regulatory Approvals - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission as a treatment option for relapsed or refractory diffuse large B-cell lymphoma, enhancing its market position [5][6] Company Overview - ADC Therapeutics is a commercial-stage biotech company focused on developing targeted cancer therapies using Antibody-Drug Conjugates (ADCs) and proprietary Pyrrolobenzodiazepine (PBD) technology [6]

Industry Overview - The Russell 2000 Index has reached new highs, indicating a renewed interest in small-cap companies, with an increase of over 13% for the year as market rotation from large-cap stocks accelerates [1][2] - Investors are shifting focus to higher-risk, higher-reward assets, reflecting growing confidence in the economy and corporate sector amid the ongoing US Federal Reserve easing cycle [2][3] - Small caps and penny stocks, previously undervalued, are gaining traction as monetary policy is perceived to be no longer tightening [3][4] Market Sentiment - A third Federal Reserve rate cut and expectations for further easing are driving interest in small companies, with the Russell 2000 Index outperforming the S&P 500 as the year ends [4] - Analysts from major financial institutions anticipate that the rotation towards small-cap stocks will continue into 2026 [4][5] Investment Strategy - The article highlights the methodology for selecting the best multibagger penny stocks, focusing on those trading under $5 with over 100% upside potential and popularity among elite hedge funds [7][8] - The strategy has historically outperformed the market, returning 427.7% since May 2014, significantly beating its benchmark [8] Company Highlights ADC Therapeutics S.A. (NYSE:ADCT) - ADC Therapeutics is identified as a top multibagger penny stock with a current share price of $4.18 and an analyst upside potential of 102.11% [9] - The company has received positive ratings from analysts, with a price target of $10.00 from Guggenheim and $5.00 from RBC Capital based on promising trial data [9][10] - The LOTIS-7 trial results show an overall response rate of 89.8% and a complete response rate of 77.6% for its drug ZYNLONTA, which has received accelerated FDA approval [11][13] Repay Holdings Corporation (NASDAQ:RPAY) - Repay Holdings is another top multibagger penny stock, currently priced at $3.40 with an upside potential of 105.88% [15] - The company is focusing on expanding its market presence and enhancing technology offerings to drive future growth, moving from negative growth and margin pressures [16][17] - Repay Holdings aims to capitalize on the $5.6 trillion market opportunity, particularly in non-discretionary transactions, while achieving over 50% free cash flow [19][20]

Group 1 - The article does not provide any specific information or data regarding companies or industries [1]

Core Viewpoint - ADC Therapeutics SA has announced updated results from the LOTIS-7 clinical trial, highlighting the potential of ZYNLONTA in treating DLBCL (Diffuse Large B-cell Lymphoma) [2][3]. Group 1: Clinical Trial Update - The LOTIS-7 clinical trial results were shared in a press release and are available on the company's website [2]. - The Chief Medical Officer, Mohamed Zaki, will provide detailed insights into the LOTIS-7 clinical trial and its updated results during the call [3]. Group 2: Strategic Overview - Ameet Mallik, the Chief Executive Officer, will present a strategic overview and discuss the opportunity for ZYNLONTA in the DLBCL market [3].

LOTIS-7 Clinical Trial Results and Strategy - The LOTIS-7 trial (ZYNLONTA + glofitamab) showed an overall response rate (ORR) of 89.8% (44/49 patients) in 2L+ LBCL patients[37] - The complete response (CR) rate in the LOTIS-7 trial was 77.6% (38/49 patients)[41] - In the LOTIS-7 trial, 6 out of 8 patients previously treated with CAR-T achieved a CR[41] - Grade 3 or higher treatment emergent adverse events (TEAEs) occurred in >5% of patients, including neutropenia (32.7%), GGT increased (16.3%), and anemia (10.2%)[40] - Grade 5 AEs occurred in 4.1% (2/49) of patients in the LOTIS-7 trial[40] - Cytokine release syndrome (CRS) of any grade was observed in 36.7% (18/49) of patients in the LOTIS-7 trial[47] Market Opportunity and Revenue Potential - ZYNLONTA has a U S peak revenue potential of $600 million to $1 billion in DLBCL and indolent lymphomas[56] - The company believes LOTIS-7 has the potential to be the leading bispecific combination regimen for patients with access to complex therapies[17] - The company believes LOTIS-5 has the potential to be the leading regimen for patients who will not receive complex therapies[17] Upcoming Milestones - The company expects full enrollment of 100 patients at selected dose for LOTIS-7 in 1H2026[59] - The company expects to share topline results for LOTIS-5[59]

3Q 2025 Earnings Call November 10, 2025 Agenda 01 Introduction Ameet Mallik Chief Executive Officer 03 Chief Financial Officer Financial Update Pepe Carmona 04 Q&A 2 Forward-Looking Statements 02 Clinical Highlights Mohamed Zaki Chief Medical Officer This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics", "we" or "us") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construe ...

Group 1 - ADC Therapeutics (ADCT) is a biotech firm focused on developing Antibody Drug Conjugates (ADCs) for cancer therapy, utilizing proprietary PBD technology to enhance treatment efficacy while minimizing damage to healthy tissue [4] - On October 16, H.C. Wainwright reaffirmed its Buy rating on ADC Therapeutics but lowered the price target from $8 to $7 following the company's announcement of a $60 million PIPE financing deal [1][2] - The PIPE financing involves the sale of 11.3 million common shares at $4.00 each and pre-funded warrants for 3.8 million shares at $3.90 each, with net proceeds expected to total approximately $57.6 million after fees and expenses [2] Group 2 - The financing strengthens ADC Therapeutics' balance sheet, increasing its pro forma cash position to an estimated $292.3 million [3] - The company anticipates reporting $15.8 million in net product revenue from ZYNLONTA sales for Q3 2025, with $234.7 million in cash and equivalents as of September 30 [3]

Group 1 - ADC Therapeutics (ADCT) is recognized as a promising long-term penny stock with significant upside potential [1] - H.C. Wainwright analyst Robert Burns has lowered the price target for ADC Therapeutics from $8 to $7 while maintaining a Buy rating [1][2] - The price target adjustment follows a $60 million private placement financing announced on October 12, which is expected to close on October 27 [2] Group 2 - The proceeds from the private placement will support the commercial expansion of ZYNLONTA, a treatment for adults with relapsed B-cell lymphoma [2] - The financing is also aimed at strengthening the company's balance sheet and positioning it for long-term growth, with potential plans for a ZYNLONTA relaunch in 2027 [2] - ADC Therapeutics specializes in antibody drug conjugate technology, focusing on transforming treatment paradigms for patients with hematologic malignancies and solid tumors [3]